BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Clears Caspofungin Susceptibility Testing for TREK Diagnostic Systems' Sensititre(R) YeastOne(R) in Vitro Diagnostics (IVD) Product Line


7/8/2009 7:00:20 AM

Bookmark and Share

CLEVELAND, July 7 /PRNewswire/ -- TREK Diagnostic Systems, a Magellan Biosciences business and premier provider of diagnostic systems and susceptibility products for microbiology labs, has received clearance from the U.S. Food and Drug Administration (FDA) to include caspofungin in its line of YeastOne susceptibility products. TREK will make the drug available on custom YeastOne formats, allowing clinicians to create the plate that best meets their requirements. The custom format complements TREK's standard IVD-cleared YeastOne product (Part No. YO-2V), which contains the four most widely-prescribed antifungals: itraconazole, fluconazole, 5 flucytosine and voriconazole.

Physicians typically prescribe intravenous caspofungin therapy when other treatment regimes are not well tolerated or have failed. The first in a new class of enzyme-inhibiting antifungal agents, caspofungin, is FDA-cleared for treatment of candidiasis in adults and pediatric patients. Candidiasis is a fungal infection that can be life-threatening if it becomes systemic.

"This is the second FDA clearance we have received this year for our YeastOne product line," said President of Magellan's diagnostics business, James Whelan. "Last month, we announced the addition of voriconazole to our standard YeastOne IVD plate. Our goal with IVD susceptibility products is to increase reportable compounds and treatment options for clinicians. Customers need plates that allow them to report timely results using a fully reimbursable format. We are committed to taking our products through the FDA clearance process where feasible and appropriate. Because pharmaceutical companies use our Sensititre susceptibility system during drug development, we often get early access to the latest therapeutics and are able to provide clinicians with the widest possible drug choices. A wide array of cost-effective plate formats that deliver timely and reliable results not only supports pharmacy cost-control efforts - it improves patient care."

About the Sensititre YeastOne Product Line

TREK offers a wide range of FDA cleared and research-use-only (RUO) YeastOne dried microbroth dilution plates with a variety of drug options. The products provide physicians and researchers with fast, cost-effective, and reliable results. Plates feature standard 24-hour incubation, easy-to-read colorimetric endpoints, and on-scale QC ranges, making antifungal susceptibility testing a viable in-house procedure for virtually any size laboratory.

* YeastOne for IVD -- The YeastOne product line received its first FDA clearance in 2001 and has been widely recognized for accuracy. TREK's standard IVD YeastOne plate (Part No. YO-2V) is the only IVD-labeled susceptibility product that is FDA-cleared for testing Candida species isolates against four commonly prescribed FDA-cleared antifungal agents: voriconazole, fluconazole, 5-flucytosine and itraconazole.

* YeastOne for RUO -- TREK's standard RUO YeastOne plate (Part No. YO-9*) includes nine antimicrobics: anidulafungin, amphotericin B, caspofungin, fluconazole, 5 flucytosine, itraconazole, micafungin, posaconazole and voriconazole.

*For research use only. Not for use in diagnostic procedures.

* Custom YeastOne plates -- Labs can customize plates by selecting from nine antifungal agents, including five cleared antifungal compounds, and specifying format and drug concentrations to create the best plate for their particular needs. Small minimum order quantities allow for better cost and inventory control. To learn more about custom plates, call customer service toll-free at 800 871-8909. Outside the US and Canada, dial +44 (0) 1342-318777 or e-mail: mmansfield@trekds.co.uk

About TREK Diagnostic Systems (www.trekds.com)

A Magellan Biosciences diagnostics business, TREK is a global manufacturer and distributor of automated systems and consumable products for microbiology-based diagnostic testing designed to improve patient outcomes. Signature product lines include VersaTREK®, Sensititre®, Vizion®, alamarBlue®, para-JEM®, YeastOne®, onSite® and TREK Lab Services. TREK is committed to delivering the highest quality products and services to clinical, pharmaceutical, and veterinary diagnostic laboratories worldwide.

Cancidas is a registered trademark of Merck & Co., Inc.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES